bluuebunny/crossref_metadata_2025_split huggingface dataset:
Influence of DNA Copy Number Aberrations in ABC Transporter Family
Genes on the Survival of Patients with Primary Operatable Non-Small Cell
Lung Cancer
Authors: Tsyganov Matvey Mikhailovich , Ibragimova Marina Konstantinovna , Rodionov Evgeny Olegovich , Frolova Anastavia Alekseevna , Tsydenova Irina Aleksandrovna , Lutzkaya Elizaveta Andreevna , Miller Sergey Viktorovich 
Published: February 2025

Purpose:
Previous research has shown, that ABC transporters gene expression level
can predict the efficacy of therapy. However, other mechanisms of gene activity are rarely considered, especially in non-small cell lung cancer (NSCLC). Thus, the purpose of the work was
to assess chromosomal aberrations of all 49 ABC transporters genes and the expression levels
of some ABC genes, as well as their correlation with survival.

Materials and Methods:
The surgical material of 104 patients with NSCLC was used in this
study. Treatment included surgery and 3 courses of adjuvant chemotherapy with “platinum
doublets”. DNA and RNA were isolated from the samples, followed by microarray analysis to
assess the expression and chromosomal aberrations (deletions and amplifications) of ABC
genes.

Results:
Metastatic-free survival (MFS) was higher with ABCC1, ABCC2, and ABCG1 hypoexpression at a statistically significant level (p=0.01). The presence of deletion in ABCB1 correlates with 100% MFS (p=0.001). The survival rates with ABCG1 amplification are not higher
than 45% (p<0.0001). ABCA11 deletion is associated with a low MFS rate (38%) versus 91%
with normal copy number (p=0.006). ABCB9 analysis showed opposite results, with survival
rates of 55% and 91% in the presence of amplification and normal copy number, respectively
(p=0.006). ABCC subfamily genes showed a similar result in the presence of amplification,
where ABCC3 and ABCC10 account for 64% and 60% survival, respectively (p=0.005, p=0.01)

Conclusion:
Thus, not only expression but also chromosomal aberrations were found to be associated with patient survival. These findings could be a
potential marker of metastatic-free
survival.
Therapeutic Potential of Simvastatin: Cellular Mechanism, Binding Energetics, and Resistance Developments
Authors: Verma Shristy , Malviya Rishabha , Sundaram Sonali , Srivastava Saurabh , Sridhar Sathvik Belagodu , Rab Safia Obaidur , Singh Deependra Pratap 
Published: February 2025

Abstract:
Statins are a class of hypolipidemic agents that have been shown to promote osteogenic
differentiation through enhanced alveolar bone recovery, inserted osseointegration, and cartilage
regeneration. This review uses Molecular Docking (MD) simulations and additional Computer-
Aided Drug Design (CADD) methods to present the state of the art in statin therapy. Furthermore,
several studies have shown that factors such as limited overall absorption, metabolism in the first
pass, and systemic side effects are among those that affect the oral administration of statins. In addition,
these variables include susceptibility to efflux mechanisms, drug permeability, dissolution
percentage, aqueous solubility, initial metabolism, and pre-systemic metabolism. Additionally examined
are the pharmacokinetics of the statin and in vivo mechanisms of action. As a result of the
numerous problems associated with the consumption of statins, including their low total bioavailability,
first-pass metabolism, low aqueous solubility, and systemic adverse reactions, a non-oral
mode of administration was looked into for this crucial and primary class of pharmacokinetic
agents. However, to optimize bioavailability and minimize side effects, more research is required.
Development and Validation of Bioenhancer-based Phospholipid Complexes with Exceptional Immunomodulatory and Antioxidant Potential
Authors: Sharma Samisha , Dwivedi Jyotsana , Dwivedi Monika , Kumari Madhu , Yadav Reenu , Khatoon Sayyada , Rawat Ajay Kumar Singh 
Published: February 2025

Background:
Combination therapy with polyphenol-rich natural spices has gained acceptance
as a proactive approach for modulating human health owing to the COVID-19 pandemic.
However, bioavailability is a significant hurdle in determining the actual potential of any herbal
drug.

Aim & Objective:
To improve the absorption of herbal drugs and to enhance their ability to affect the
immune system, phospholipid complexes were developed for accommodating Curcumin with extracts
of commonly found dietary spices like Piper longum, Piper nigrum, and Zingiber officinale
aiming to have an effective immunomodulatory phytoformulation subduing the bioavailability limitation
of Curcumin and delivery hurdle of phytoextracts for combination therapy. Since combination
therapy with polyphenol-rich natural spices had surfaced as an effective mode of immunomodulation,
phospholipid complexes were designed for encapsulating polyphenol-rich natural spices and
Curcumin together and assessed for the most efficient phospholipid complexes with improved invitro
therapeutic outcomes.

Method:
A quick and easy procedure for assessing the developed formulation using High-
Performance Thin-Layer Chromatography (HPTLC) was developed. Antioxidant potential was
measured by DPPH and Lipid peroxidation. Further immunomodulation was assessed in macrophages
by NO inhibition assay and phagocytosis capacity.

Result:
The results showed that polyherbal phospholipid complexes exerted 2-fold enhanced antiradical
properties (DPPH radical scavenging and inhibition of lipid peroxidation) as compared to
Curcumin and significant inhibition of ROS in H2O2-induced human macrophages. Moreover, these
polyherbal formulations were more effective in promoting macrophage proliferation, inhibiting LPSinduced
NO production in macrophages, and enhancing phagocytosis in a dose-dependent manner.

Conclusion:
Thus, phospholipid complexes offer a practical approach for developing nutraceuticals
with augmented bioactivity of herbal components.
Critical Analysis of Non-profit Clinical Trials: Three Years of Activity at the Clinical Trials Office
Authors: Dri Diego Alejandro , De Cata Marta , Carafa Maria , De Paola Eleonora , Maione Raffaella , Aita Paola , Gramaglia Donatella 
Published: February 2025

Introduction:
Non-profit clinical trials submitted for authorization over three years to
the Clinical Trials Office of the Italian Medicines Agency were reviewed and critically analyzed.

Objective:
The objectives are to highlight potential trends following the full implementation of
Regulation (EU) No. 536/2014 and to reveal the different nuances of non-profit clinical trials,
comparing them with the general profile of all clinical trials.

Methods:
Using a multidisciplinary approach, the research navigates public data, official
documents and data retrieved from the Italian National Observatory on Clinical Trials and from
the European Clinical Trials Information System to reveal shifts in the clinical trials landscape.

Results:
A decrease in non-profit applications submitted in the 2020-2022 timeframe is
emerging, clearly related to the new regulatory complexities and uncertainties in the adoption of
the Clinical Trials Information System platform. Results also show a divergence between nonprofit
and overall clinical trials in terms of authorization outcomes, also including studies with a
COVID-19 indication. Further comparing non-profit studies with the total number of clinical
trials across different characteristics, such as phases, therapeutic areas and study purposes,
increases transparency and availability of insight information.

Conclusion:
Relevant data are provided as a result of the review and analysis of non-profit
clinical trials, highlighting specific features. Overall, this critical analysis provides an overview
of recent trends and, also promotes insights for further consideration by regulators to adequately
support clinical research in a complex and evolving regulatory environment.
Fully Covered Self-Expandable Metal Stents for the Treatment of Leak after Oncologic Gastroesophageal Surgery: A Cohort Study
Authors: Luigiano Carmelo , Di Leo Milena , Magistroni Marco , Iabichino Giuseppe , Arena Monica , Consolo Pierluigi , Palamara Maria Angela , Abenavoli Ludovico , De Luca Luca 
Published: February 2025

Background:
Anastomotic leakages are one of the most frequent complications of gastroesophageal
surgery with a high mortality.

Objective:
This study aimed to assess the efficacy and safety of endoscopic therapy using fully
covered self-expanding metal stents (FC-SEMS) for the management of anastomotic leaks.

Methods:
In this cohort study, all patients with leak after oncological gastroesophageal surgery
treated with FC-SEMS were included. Procedures were performed by one expert endoscopist in
three Italian endoscopic units. The primary outcome was clinical success defined as complete resolution
of clinical and laboratory manifestations of sepsis with radiological evidence of leak closure.
Secondary outcomes were technical success, stent-related adverse events (AEs), and mortality.

Results:
28 patients (21.4% female, mean age 64.3 years) were included in the study, of whom 17
(60.7%) had undergone total gastrectomy, 9 (32.1%) Ivor-Lewis procedure, and 2 (7.1%) extended
gastrectomy (transhiatal-abdominal approach). The leaks were located in esophagogastric anastomosis
in 5 patients (17.9%), esophagojejunal anastomosis in 19 (67.9%), and esophagus in 4
(14.3%). A total of 34 stents were placed (mean of 1.2 per patient). Technical success of stent
placement was achieved in all cases (100%). Clinical success was observed in 78.6% of patients.
Stent-related early AEs occurred in 9 patients (32.1%, all were migration). Late AEs occurred in
21.4%, which all were treated endoscopically.

Conclusion:
Stenting therapy using FC-SEMS is a safe and effective modality for the management
of anastomotic leaks.
Antibody Drug Conjugates (ADCs): Shaping the Future of Precision Oncology
Authors: Sevilla-Carrillo Irene , García-Tercero Eloína , Alonso-Moreno Carlos , Moya-Lopez Carmen 
Published: February 2025

Abstract:
Antibody-drug conjugates (ADCs) are a groundbreaking advancement in targeted cancer therapy,
combining the precision of monoclonal antibodies with the potency of cytotoxic drugs. This review first outlines
the components of ADCs and their mechanisms of action before providing a comprehensive overview of the
current state of ADC technology. It covers both FDA-approved ADCs and those in various stages of clinical
development, as well as future research directions. The review also explores recent innovations, such as bispecific
antibodies and pro-body-drug conjugates, which offer promising new strategies for improving efficacy and minimizing
off-target effects. The review emphasizes the need for ongoing research to optimize ADC design and
develop novel approaches to enhance their therapeutic potential.
In vitro and In vivo Growth Inhibition and Apoptosis of Cancer Cells by Ethyl 4-[(4-methylbenzyl)oxy] Benzoate Complex
Authors: Auwal Abdul , Al Banna Md. Hasan , Pronoy Tasfik Ul Haque , Hossain M. Matakabbir , Rashel KM , Kabir Syed Rashel , Ansary Md. Rezaul Haque , Islam Farhadul 
Published: February 2025

Background:
Cancer chemotherapy is one of the best ways to treat the patients with cancer as they can
remove cancer cells, which can’t be remove by radiation or surgery.

Aims:
Our study is focused on identifying potent chemotherapeutic drugs with minor or no adverse side effects.
Therefore, in this study, we aimed to synthesize ethyl 4-[(4-methylbenzyl)oxy] benzoate complex, a macrocyclic
aromatic compound followed by testing its antineoplastic activity against Ehrlich ascites carcinoma (EAC) human
breast cancer (MCF7) cells.

Methods:
In vitro and in vivo assays were used for monitoring, cytotoxicity, tumor weight, survival time, tumor
cell growth inhibition, and hematological parameters to investigate the anticancer effectiveness of the tested compound.
Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) was used to examine the expression
of growth and apoptotic related genes. Haematological and biochemical parameters were assessed to examine
the host toxicity in mice.

Results:
The compound exhibited notable anticancer activity against both EAC and MCF7cells. It showed 40.70
and 58.98 % cell growth inhibition at the doses of 0.5 and 1.00 mg/kg, respectively in comparison to that of control
EAC-bearing mice (p < 0.0001). The result is comparable with clinically used chemotherapeutic drugs cisplatin
(59.2% growth inhibition at the dose of 1.0 mg/kg body weight). A four folds reduction of tumor weight (volume)
of treated group at higher dose (1.0 mg/kg/day) was noted in comparison to that of untreated EAC-bearing
mice. Also, the mean survival time of treated mice (1.00 mg/kg) increased by more than 83.07% when compared
to that of control EAC-bearing mice (p<0.001). In addition, EAC-bearing control mice showed drastic deterioration
of RBC, WBC, and % of hemoglobin, however, in the treated mice these parameters were restored towards
normal levels. A dose dependent reduction of growth and proliferation of MCF7 cells was noted in compound
treated cells. Most importantly, apoptosis of MCF7 was induced followed by activation of pro-apoptotic genes
(p53, Bax, Parp, Caspase-3, -8, -9) and inactivation of antiapoptotic, e.g. Bcl2 gene. Toxicological studies reveal
that there were changes in hematological (RBC, WBC, % of Hb) and biochemical (serum glucose, cholesterol,
creatinine, SGOT, SGPT) parameters during the treatment period, however, the parameters returned towards
normal levels after the treatment period, indicating no or minor toxic effect of the compound on the host.

Conclusion:
The compound has promising anticancer activity with no or minimum host toxic effects. Thus, it has
the potential to be formulated as an effective chemo-agent, however, further preclinical and clinical research is
imperative using animal and human models.
Dimethyl Fumarate Attenuates Behavioral and Structural Impairments
Associated with Brain Ischemia in Rats
Authors: Bakhtiari Mohammad , Emamghoreishi Masoumeh , Ardakani Maryam Khastkhodaei , Namavar Mohammad Reza 
Published: February 2025

Introduction:
Ischemic stroke remains one of the leading causes of death and physical
and mental disability. Oxidative stress, free radicals, and inflammation play critical roles in ischemic brain damage. Free radical scavengers such as edaravone and dimethyl fumarate (DMF),
known for their antioxidant and anti-inflammatory properties, are considered promising targets for
ischemic stroke treatment. This study aimed to assess the impact of these drugs on brain ischemia

Methods:
Forty-nine rats were randomly divided into seven groups: sham, edaravone, and DMF
controls, as well as edaravone, DMF 5, 15, and 30 groups. Middle cerebral artery occlusion
(MCAO) was induced in all groups except the sham group. The MCAO groups were administered
with either the vehicle, edaravone (3 mg/kg), or DMF at doses of 5, 15, and 30 mg/kg twice daily
for 14 days. Neurobehavioral assessments were conducted throughout the experiment, and anatomical changes in the brain were evaluated using stereological methods.

Results:
Edaravone and three doses of DMF improved neurobehavioral functions. All treated rats
showed a reduction in the ischemic volume and cell loss in the brain regions when compared with
the control animals. MCAO reduced the total number of neurons and just DMF doses had a significant effect on this factor. Interestingly, MCAO increased the number of non-neurons and only the
DMF 30 group significantly decreased this parameter. DMF 30 was more effective in ischemic
stroke.

Conclusions:
Although edaravone improved neurological functions and reduced the size of brain
ischemia and cell loss, DMF, especially at higher doses, exerted a more beneficial effect on these
parameters. Therefore, DMF could be proposed as a reinforcement to currently conventional therapies.
Bioactive Polyphenolic and Terpenoid Compounds from Stem Bark and Flowers of Terminalia brownii
Authors: Ikikii Sebastian M. , Odalo Josiah O. , Ogweno Aloice O. , Heydenreich Matthias 
Published: February 2025

Introduction

Terminalia brownii Fresen (Combretaceae) extensively used in Eastern, Southern, and Western Africa herbal remedies in treatment of variety of diseases including liver cirrhosis. Bioassay – guided fractionation was used to isolate the compounds responsible for these actions.

Aim of the Study
The study sought to extract, characterize and determine the antimicrobial activities of the components of the commonly used stem bark and hitherto uninvestigated regeneratable flowers of T.brownii.

Materials and Methods
Column chromatography was used to fractionate and isolate the compounds followed by thin layer chromatography. The isolates were structurally elucidated using FTIR, 1H NMR, 13C NMR and HRESI-MS spectral data. The isolated compounds' antimicrobial activities were evaluated against Candida albicans, Staphylococcus aureus, Pseudomonas aeruginosa and Escherichia coli.

Results
Bioassay – guided fractionation of methanol and 50% dichloromethane: methanol extracts of Terminalia brownii stem bark and flowers yielded seven known metabolites; termiglaucescin (1), arjunglucoside-I (2), sericoside (3), 23-galloyl arjungenin (4), 28-O-β-D-glucopyranosyl-2,3,6-trihydroxy-23-galloylolean-12-dien-28-oate (5), 3,3',4',5-tetrahydroxy-7-methoxyflavone (9), 3,3',4',5,7-pentahydroxyflavone (10) and three new metabolites: 1,4,7-tri-O-galloyl hept-6-deoxyheptose (6), 1,2,4-tri-O-galloyl-8,9-dideoxynonose (7), Rhamnetin-3-O-(2,3,6-trigalloyl)-β-D-glucopyranoside (8). Among these molecules, compound (6) was extremely potent toward E. coli (16.5±0.7 mm) while (1) showed substantial inhibitory effects on Candida albicans (16.0±5.7 mm). Compounds 6, 7, 8, 9, and 10 were extracted and identified for the first time from 50% dichloromethane/methanol flower extract. The extract yielded three novel bioactive compounds (6, 7 and 8) that shown substantial activity on P.aeruginosa, E. coli, C. albicans, S. aureus.

Conclusion
For the first time, the results of this investigation demonstrate that flower extract possess strong antibacterial and antifungal qualities, akin to those of stem bark extract. As a result, more environmentally friendly flower extracts should be considered for treatment of bacterial and fungal infection.
Novel Delivery Approaches and Therapeutic Potential of Resveratrol – A Review
Authors: Nooreen Zulfa , Rai Awani Kumar , Wal Pranay , Bhise Manish , Balaji Jadhav , Gasmi Amin 
Published: February 2025

Abstract:
Resveratrol (RV) is a well-known polyphenolic compound found in many different
plants, including the fruits of grape, peanut, and berry trees. It is well-known for its links to a number
of health benefits, including those related to glucose metabolism, anti-aging, anti-tumor, antiobesity,
anticancer and neuroprotective effects. Promising therapeutic properties have been reported
in multiple cancers, neurodegenerative diseases, and atherosclerosis. These properties are regulated
by multiple synergistic pathways that govern inflammation, oxidative stress, and cell death. RV also
has a potent anti-adipogenic effect by preventing fat accumulation and triggering lipolytic and oxidative
pathways. By preventing platelet aggregation, it demonstrates its cardioprotective properties.
RV also has a potent anti-adipogenic effect by preventing fat accumulation and triggering lipolytic
and oxidative pathways. By preventing platelet aggregation, it demonstrates its cardioprotective
properties.To increase resveratrol's dissolution, stability, oral bioavailability, and regulated evacuation,
nanotechnologies have become widely used.RV's drug-delivery methods linked to bioavailability
have additionally been extensively utilised, and RV nanoparticles and liposomes seem to be
viable platforms for improving their bioavailability. The current review seeks to give an organised
summary of the medicinal advantages and recent discoveries.
Natural Extract-Loaded Herbal Patches: Assessment for Biomedical
Application
Authors: Ansari Shaheen , Pragya  , Srivastava Shikha , Parashar Poonam 
Published: February 2025

Introduction and Objective:
Medicinal plants like Moringa and Selaginella have
gained attention for their potential in wound healing including antimicrobial and antioxidant attributes. Extracts from these plants have shown promise in accelerating wound healing processes,
enhancing fibroblast cell proliferation and migration, and providing antioxidant benefits. The objective of this work was to assess the therapeutic potential of extracts loaded patches for biomedical applications.

Methods:
Selaginella bryopteris L. and Moringa oleifera Lam. extracts were prepared using the
cold maceration method. The prepared extracts were evaluated for antibacterial activity and antioxidant potential. Additionally, patches were prepared using Polyvinyl Alcohol and Hydroxypropyl Methylcellulose as polymers and evaluated for in vitro release and cell viability and biocompatibility characteristics

Result:
The extract of both plants showed good antioxidant potency against ascorbic acid. Antibacterial activity revealed that Selaginella and Moringa extracts and patches consistently outperformed P. aeruginosa, B. subtilis, and S. aureus at varying concentrations. Physiochemical evaluation of patches indicated good weight uniformity, thickness, and folding endurance, with slight
moisture uptake. Drug release profiles showed significant results for all formulations. The results
of cell viability for patches showed an increased cell proliferation and were nontoxic.

Conclusion:
The study suggests that both extract and patch show excellent antibacterial activity
against Staphylococcus aureus. The characterization results showed that the patches were uniform
in their drug content, weight, and thickness, and they also indicated the reproducibility of the
method used. In the in vitro release study of Selaginella bryopteris L. and Moringa oleifera Lam.
patches were fitted to the Higuchi model and also patches were found harmless for the cells as
well as increased proliferation of cells.
Novel Therapeutic Approaches Emerging in the Field of Onychomycosis
Authors: Garg Gurisha , kamal Raj , Garg Sonakshi , Patel Preeti , Kurmi Balak Das 
Published: February 2025

Abstract:
Onychomycosis is regarded as one of the most common and least concerned
fungal problems. Although various treatment approaches have been well-established, still
treatment strategies suffer from certain drawbacks, so there is a need to discuss novel therapies
that could ultimately eliminate all the conventional barriers. It is a nail infection that
begins in the toenail and spreads, causing significant negative impacts on patients' quality
of life. The purpose of this work was to highlight the limitations of conventional treatments
and shed light on novel therapies for managing onychomycosis. A comprehensive review
on existing topical and systemic therapies was conducted, with a focus on their drawbacks,
such as recurrence and lower efficacy. This review aimed to explore the increasing prevalence
of onychomycosis, which poses a serious health issue; however, the advent of nanobased
drug delivery systems offers hope for more effective management of this prevalent
disease. These systems could potentially overcome the limitations of conventional treatments,
thereby improving patient outcomes.
Presentación dossier sobre cultura y migración
Authors: Lucotti Claudia 
Published: February 2025

Cultura y migración son dos términos muy cargados de gran actualidad y relevancia, razón por la cual se pueden abordar desde diversos enfoques, lo cual a su vez puede resultar en que adquieran connotaciones diferentes. En las siguientes líneas intentaré hacer un breve acercamiento a estos temas desde un enfoque en particular, el de los Estudios Culturales, por considerar que es el que me permite comentar y poner en diálogo de manera iluminadora los cuatro textos que componen este dossier.